治疗多发性骨髓瘤新药帕比司他

发布时间：2018-08-14 11:20

【摘要】：综述帕比司他联合硼替佐米和地塞米松治疗前期至少2种治疗方案(硼替佐米联合免疫调节剂)失败的多发性骨髓瘤(MM)的新治疗方案的作用机制、药效学、药动学、临床评价和安全性。本品作为组蛋白去乙酰化酶抑制剂(HDACi),对复发/难治型MM具有较高活性。动物实验和临床试验结果显示本品对MM有很好的疗效,但需关注其药物不良反应和药物间相互作用。帕比司他可增加无进展生存期(PFS)并且更益于MM治疗,是MM患者的又一治疗选择。
[Abstract]:To review the mechanism, pharmacodynamics and pharmacokinetics of at least two new protocols (bortezomil combined with immunomodulator) for the treatment of failed multiple myeloma (MM) in the early stage of treatment of multiple myeloma (MM) with parbesmast combined with bortezomil and dexamethasone (Dexamethasone). Clinical evaluation and safety. (HDACi), a histone deacetylase inhibitor, has high activity for recurrent / refractory MM. The results of animal and clinical trials showed that the drug had a good effect on MM, but attention should be paid to its adverse drug reactions and drug interactions. Pabestat can increase (PFS) and be more beneficial to MM treatment, which is an alternative treatment for MM patients.
【作者单位】：中国医学科学院北京协和医院药剂科;北京市昌平区中西医结合医院药剂科;
【分类号】：R979.1

【相似文献】